Lichtenstein, Henri,Edwards, Nicholas,Ritchie, James,Petersen, Kamille Dumong,Plumb, Jane
申请号：
AU2013205999
公开号：
AU2013205999A1
申请日:
2013.05.23
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
#$%^&*AU2013205999A120130613.pdf#####ABSTRACT The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer hernatological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, Avastin*, an antibody against -CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount. 20073321.doc4/5 FIGURE 4 12001000800- Tumour volume (mean/SEM) E PXD101, 80 mg/kg i.p. E 00 Avastin, 5 mg/kg i.p. 0 > 400 0 E 200 -0 0 2 4 6 8 10 12 14 16 18 T Days Avastin Untreated -+-- Avastin(5), day 4 + PXD101(80), day 0-4 + Avastin(5) - -M- - PXD1 01(80), day 0-8 + Avastin(5) -- PXD101(80), day 4-8 + Avastin(5)
